| 2026-03-16 |
Sarepta Therapeutics, Inc. |
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne sarepta.com ↗ |
| 2026-02-24 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan sarepta.com ↗ |
| 2026-01-26 |
Sarepta Therapeutics, Inc. |
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients sarepta.com ↗ |
| 2026-01-23 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy sarepta.com ↗ |
| 2025-11-25 |
Sarepta Therapeutics, Inc. |
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne sarepta.com ↗ |
| 2025-11-14 |
Sarepta Therapeutics, Inc. |
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information sarepta.com ↗ |
| 2025-07-28 |
Sarepta Therapeutics, Inc. |
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy sarepta.com ↗ |
| 2025-07-25 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS sarepta.com ↗ |
| 2025-07-25 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union sarepta.com ↗ |
| 2025-07-21 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. sarepta.com ↗ |
| 2025-07-18 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Provides Statement on ELEVIDYS sarepta.com ↗ |
| 2025-07-16 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label sarepta.com ↗ |
| 2025-06-15 |
Sarepta Therapeutics, Inc. |
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne sarepta.com ↗ |
| 2025-05-21 |
Sarepta Therapeutics, Inc. |
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy sarepta.com ↗ |
| 2025-05-13 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy sarepta.com ↗ |
| 2025-04-04 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Provides Update on ELEVIDYS sarepta.com ↗ |
| 2025-01-27 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS sarepta.com ↗ |
| 2024-06-20 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above sarepta.com ↗ |
| 2024-02-16 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication sarepta.com ↗ |
| 2023-12-22 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status sarepta.com ↗ |
| 2023-10-30 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy sarepta.com ↗ |
| 2023-06-22 |
Sarepta Therapeutics, Inc. |
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy sarepta.com ↗ |
|